

Supporting Information:

Transferrin Conjugated Nontoxic Carbon Dots for Doxorubicin Delivery to Target Pediatric Brain Tumor Cells

Shanghao Li^{1,§}, Daniel Amat^{1,§}, Zhili Peng¹, Steven Vanni², Scott Raskin³, Guillermo De Angulo³, Abdelhameed M. Othman,^{4,5,} Regina M. Graham², and Roger M. Leblanc^{1,*}*

¹Department of Chemistry, University of Miami, 1301 Memorial Drive, Coral Gables, Florida, 33146, United States

²Department of Neurological Surgery, Miller School of Medicine, University of Miami, Miami, Florida, 33136, United States

³Nicklaus Children's Hospital, Miami, Florida, 33155, United States

⁴Department of Chemistry, Faculty of Science in Yanbu, Taibah University, Yanbu, Saudi Arabia

⁵Department of Environmental Biotechnology, Genetic Engineering and Biotechnology, University of Sadat City, Sadat City, Egypt

[§]These two authors contribute equally.

*Corresponding authors R.M.L. Tel.: +1-305-284-2194; Fax: +1-305-284-6367. E-mail: rml@miami.edu. A.M.O. Tel.: +966-560-251-254. E-mail: hameed.mahmoud61@hotmail.com.

Keywords: Anti-Cancer; Carbon Dots; Doxorubicin; Drug Delivery; Pediatric Brain Tumors; Transferrin




Figure SI-1. Pediatric Brain Tumor Cell lines. Characteristics of cell lines used in this study (A), and Western blot analysis of TFR1 levels in multiple pediatric brain tumor cell lines (B). CHLA-259 (Medulloblastoma) CHLA-266sp refers to the stem-like cell population, GBM-glioblastoma, ATRT-Atypical teratoid/rhabdoid tumor, PD-progressive disease.